SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?


To: Rudy Saucillo who wrote (1517)10/25/1998 4:03:00 PM
From: Jason Chesshir  Read Replies (1) | Respond to of 2173
 
What are the medical merits of EXENDIN-4? I believe Eli Lilly is developing a drug(synthetic analogs of GLP-1) very similar in properties of Exendin-4 but has a plasma half-life which is too short to make a commercially useful product while Exendin-4 offers a much longer biological duration of action.

As rumor would have it, if any backing where to surface it would be from Eli Lilly.